Emory Integrated Metabolomics and Lipidomics Core

These analyses provide a deeper understanding of lipid mediators and soluble metabolites whose abundance can be monitored as biomarkers to predict and track the progression of various diseases, including metabolic disorders such as obesity, Type 2 diabetes and nonalcoholic fatty liver disease (NAFLD), neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, and certain cancers, including prostate and breast cancer.

The Emory Integrated Metabolomics and Lipodmics Core is supported by Emory Neuroscience NINDS Core Facilities, Georgia Clinical & Translational Science Alliance and Emory University School of Medicine. It is subsidized by the Emory University School of Medicine and is one of the Emory Integrated Core Facilities.

The National Cancer Institute requires that publications acknowledge the Winship Cancer Institute Cancer Center Support Grant (CCSG), and it is tracking compliance. If a Winship Cancer Institute CCSG-supported Shared Resource provided data, designed the study, performed analyses, provided results used in your publication, and/or provided any systems or services that were used for the work that resulted in your publication, please include the following statement in the acknowledgment section of your publication(s):

Research reported in this publication was supported in part by the Emory Integrated Metabolomics and Lipidomics shared resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.